20 completed. 20 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Completed 20 |
| Phase 2 | 2 | Completed 2 |
Follow Secondary Hyperparathyroidism: new trials by email Literature Review of Secondary Hyperparathyroidism trials Research Report on Secondary Hyperparathyroidism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Trial of SHR6508 in Secondary Hyperparathyroidism SHR6508 plus oral placebo tablets, Cinacalcet plus intravenous placebo - Secondary Hyperparathyroidism | Phase 3 | Completed | Shanghai Hengrui Pharmaceutical Co., Ltd. | 498 | 2024-06-14 | 2025-12-12 |
| Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2 PLS240, Placebo, Open-Label Extension PLS240 - Secondary Hyperparathyroidism, End Stage Kidney Disease | Phase 3 | Completed | Pathalys Pharma | 412 | 2023-05-15 | 2025-09-09 |
| Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1 PLS240, Placebo, Open-Label Extension PLS240 - Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD) | Phase 3 | Completed | Pathalys Pharma | 362 | 2023-04-28 | 2025-09-09 |
| Injection of Teriparatide to Prevent Hypocalcemia After Parathyroidectomy in Dialysis Patients (TeriCa). Teriparatide - Secondary Hyperparathyroidism, Chronic Kidney Disease-Mineral and Bone Disorder | Phase 3 | Completed | Saint Petersburg State University, Russia | 20 | 2021-03-01 | 2022-11-10 |
| Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia KHK7580, Cinacalcet Hydrochloride - Secondary Hyperparathyroidism | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 404 | 2019-04-09 | 2022-04-25 |
| Phase 3 Study of SK-1403 SK-1403, Placebo - Secondary Hyperparathyroidism | Phase 3 | Completed | Sanwa Kagaku Kenkyusho Co., Ltd. | 153 | 2019-01-21 | 2020-03-09 |
| SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis SK-1403 - Secondary Hyperparathyroidism | Phase 3 | Completed | Sanwa Kagaku Kenkyusho Co., Ltd. | 157 | 2018-09-13 | 2020-03-09 |
| Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Etelcalcetide, Cinacalcet - Secondary Hyperparathyroidism, Chronic Kidney Disease | Phase 3 | Completed | Amgen | 637 | 2018-05-15 | 2021-04-30 |
| Phase 3 Study of KHK7580 KHK7580 - Secondary Hyperparathyroidism | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 39 | 2015-09-29 | 2017-07-05 |
| Phase 3 Study of KHK7580 KHK7580 - Secondary Hyperparathyroidism | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 137 | 2015-09-28 | 2017-07-05 |
| Phase 3 Study of KHK7580 KHK7580, KRN1493 - Secondary Hyperparathyroidism | Phase 2 / Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 634 | 2015-09-01 | 2017-03-24 |
| Head-to-Head Study of Etelcalcetide (AMG 416) and Cinacalcet Etelcalcetide, Cinacalcet, Oral Placebo - Secondary Hyperparathyroidism, Chronic Kidney Disease | Phase 3 | Completed | Amgen | 683 | 2013-08-13 | 2019-07-18 |
| A Study to Evaluate the Safety of Paricalcitol Capsules in Pediatric Subjects Ages 10 to 16 With Stage 5 Chronic Kidney Disease Receiving Peritoneal Dialysis or Hemodialysis paricalcitol - End-Stage Renal Disease, Secondary Hyperparathyroidism | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 13 | 2011-10-01 | 2018-07-02 |
| Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Hemodialysis With Secondary Hyperparathyroidism paricalcitol, maxacalcitol, paricalcitol placebo - Secondary Hyperparathyroidism, Hemodialysis | Phase 3 | Completed | AbbVie (prior sponsor, Abbott) | 255 | 2011-05-01 | 2013-06-06 |
| Safety/Efficacy Study of CTAP101 in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism (SHPT) Cohort 1 CTAP101 Capsules- 60µg, Cohort 1 CTAP101 Capsules - 90µg, Cohort 1 Matching Sugar Capsule - Chronic Kidney Disease, Secondary Hyperparathyroidism | Phase 2 / Phase 3 | Completed | OPKO Health, Inc. | 78 | 2010-10-01 | 2016-08-25 |
| E.V.O.L.V.E. Trial™: EValuation Of Cinacalcet Hydrochloride (HCl) Therapy to Lower CardioVascular Events Cinacalcet, Placebo - Secondary Hyperparathyroidism, Chronic Kidney Disease | Phase 3 | Completed | Amgen | 3883 | 2006-08-22 | 2022-11-07 |
| SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism cinacalcet - Secondary Hyperparathyroidism, End Stage Renal Disease | Phase 3 | Completed | Amgen | 673 | 2004-09-01 | 2013-05-23 |
| A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis Placebo, AMG 073 - Secondary Hyperparathyroidism, End Stage Renal Disease | Phase 3 | Completed | Amgen | 380 | 2002-05-01 | 2013-05-08 |
| A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients AMG 073, Placebo - Secondary Hyperparathyroidism, End Stage Renal Disease | Phase 3 | Completed | Amgen | 400 | 2001-12-01 | 2013-05-08 |
| Calcium and Vitamin D Malnutrition in Elderly Women calcium supplementation, calcium and vitamin D3 supplementation, Placebo - Osteoporosis, Secondary Hyperparathyroidism | Phase 3 | Completed | Creighton University | 1180 | 2000-05-01 | 2008-08-11 |
Hyperparathyroidism, Secondary (20) · Kidney Failure, Chronic (7) · Renal Insufficiency, Chronic (4) · Chronic Kidney Disease-Mineral and Bone Disorder (1) · Hyperparathyroidism (1) · Hypocalcemia (1) · Hypoparathyroidism (1) · Kidney Diseases (1) · Osteoporosis (1) · Osteoporotic Fractures (1) · Parathyroid Diseases (1) · Renal Insufficiency (1)
Endocrine System Diseases (20) · Hyperparathyroidism (19) · Parathyroid Diseases (19) · Chronic Disease (11) · Disease Attributes (11) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Male Urogenital Diseases (11) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Urogenital Diseases (11) · Urologic Diseases (11) · Kidney Diseases (10) · Renal Insufficiency (9) · Renal Insufficiency, Chronic (6)
Cinacalcet (9) · etelcalcetide hydrochloride (2) · paricalcitol (2) · Calcium (1) · Teriparatide (1) · maxacalcitol (1)
Amgen (6) · Kyowa Kirin Co., Ltd. (4) · AbbVie (prior sponsor, Abbott) (2) · Pathalys Pharma (2) · Sanwa Kagaku Kenkyusho Co., Ltd. (2) · Creighton University (1) · OPKO Health, Inc. (1) · Saint Petersburg State University, Russia (1) · Shanghai Hengrui Pharmaceutical Co., Ltd. (1)
Japan (6) · United States (4) · China (3) · Poland (3) · Portugal (3) · Spain (3) · Bulgaria (2) · Hong Kong (2) · Russia (2) · Serbia (2) · South Korea (2) · Taiwan (2) · Austria (1) · Belgium (1) · Canada (1)
Ann Eldred, MD (1) · Joan M Lappe, Ph.D (1) · Joel Melnick, MD (1) · Kazuya Kobayashi, BA (1)
PMID 15689407, PMID 16105056, PMID 17556697, PMID 18793528, PMID 24128439, PMID 25404192, PMID 25710802, PMID 25851955, PMID 25887067, PMID 26059012, PMID 27080930, PMID 28332096, PMID 29525393, PMID 30955188, PMID 35176038, PMID 36512619, PMID 37696667, PMID 41078042
2023 (2)